Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRN 1008

Next Previous
Drug Profile

PRN 1008

Alternative Names: PRN-1008

Latest Information Update: 21 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Principia Biopharma
  • Class Anti-inflammatories; Nitriles; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pemphigus vulgaris
  • Phase II Idiopathic thrombocytopenic purpura
  • No development reported Autoimmune disorders

Most Recent Events

  • 07 Dec 2019 Efficacy and adverse events data from a phase I/II trial in Immune Thrombocytopenic Purpura presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 15 Oct 2019 Preliminary efficacy and adverse events data from a phase II trial in Idiopathic thrombocytopenic purpura released by Principia Biopharma
  • 11 Oct 2019 Efficacy and safety data from a phase II Believe-PV trial in Pemphigus vulgaris released by Principia Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top